Gorman Kevin Charles
- SEC CIK
- 0001201096
In the past year, 2 open-market sale filings worth $37.9M and no purchases.
Current role at each company
- NBIX Neurocrine Biosciences IncDirectoras of Sep 15, 2026
- XNCR Xencor IncDirectoras of Jul 8, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $37.9M
- 2 filings
- Net
- −$37.9M
- Bought minus sold
- Companies
- 2
- With open-market trades
Trades
Every Form 4 that lists Gorman Kevin Charles as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
XNCR Xencor Inc
Director4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 15, 2024 (view filing) | Feb 13 | 2 days | Gorman Kevin CharlesDirector | PPurchase | +53 | $19.12 | +$1.01K | +1.1%5.06K after | |
| Oct 1, 2024 (view filing) | Sep 27 | 4 days | Gorman Kevin CharlesDirector | SSale | −2.65K | $20.68 | −$54.9K | −24.0%8.39K after | |
| Jun 16, 2025 (view filing) | Jun 16 | Same day | Gorman Kevin CharlesDirector | SSale | −3.17K | $9.22 | −$29.3K | −14.4%18.9K after | 10b5-1 |
| Jun 17, 2026 (view filing) | Jun 15 | 2 days | Gorman Kevin CharlesDirector | SSale | −7.53K | $12.31 | −$92.7K | −39.8%11.4K after | 10b5-1 |
NBIX Neurocrine Biosciences Inc
Director15 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 9, 2022 (view filing) | Feb 7-8 | 2 days | Gorman Kevin CharlesChief Executive Officer | SSale | −11.0K | $80.54 | −$884.7K | −2.3%462.8K after | 4 lots |
| Feb 2, 2023 (view filing) | Jan 31 | 2 days | Gorman Kevin CharlesChief Executive Officer | SSale | −2.71K | $110.08 | −$298.0K | −0.6%465.3K after | |
| Feb 8, 2023 (view filing) | Feb 6-8 | 2 days | Gorman Kevin CharlesChief Executive Officer | SSale | −29.0K | $102.90 | −$2.99M | −5.6%491.4K after | 4 lots |
| Aug 23, 2023 (view filing) | Aug 21 | 2 days | Gorman Kevin CharlesChief Executive Officer | SSale | −9.33K | $107.40 | −$1.00M | −1.8%499.8K after | 10b5-1 |
| Jan 10, 2024 (view filing) | Jan 8-9 | 2 days | Gorman Kevin CharlesChief Executive Officer | SSale | −167.9K | $133.02 | −$22.3M | −25.1%499.8K after | 2 lots10b5-1 |
| Feb 2, 2024 (view filing) | Jan 31 | 2 days | Gorman Kevin CharlesChief Executive Officer | SSale | −2.71K | $140.69 | −$380.8K | −0.5%502.2K after | 10b5-1 |
| Feb 8, 2024 (view filing) | Feb 6-8 | 2 days | Gorman Kevin CharlesChief Executive Officer | SSale | −5.31K | $138.74 | −$737.3K | −1.0%507.0K after | 2 lots10b5-1 |
| Feb 15, 2024 (view filing) | Feb 13 | 2 days | Gorman Kevin CharlesChief Executive Officer | SSale | −2.83K | $133.02 | −$376.7K | −0.5%514.6K after | 10b5-1 |
| Jan 29, 2025 (view filing) | Jan 27 | 2 days | Gorman Kevin CharlesDirector | SSale | −146.1K | $149.46 | −$21.8M | −22.1%514.6K after | 10b5-1 |
| Feb 4, 2025 (view filing) | Jan 31 | 4 days | Gorman Kevin CharlesDirector | SSale | −2.71K | $152.92 | −$414.0K | −0.5%517.0K after | 10b5-1 |